NYSE$RMD
ResMed Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
ResMed's revenue increased, driven by strong sales growth in the Americas and overall solid performance across 140 countries.
ResMed Inc. reported a 16% increase in revenue to $1,033.7 million and a diluted earnings per share of $1.53 for the second quarter of fiscal year 2023. The company's performance was driven by increased production and delivery of flow generator devices to meet customer demand and the acquisition of MEDIFOX DAN.
- Revenue increased by 16% to $1,033.7 million, or 20% on a constant currency basis.
- Diluted earnings per share reached $1.53, with non-GAAP diluted earnings per share at $1.66.
- The acquisition of MEDIFOX DAN expanded the company's SaaS business outside the U.S.
- The company significantly increased production and delivery of flow generator devices.
Headline financials
Revenue & EPS history
ResMed · Revenue · Quarterly
$1.03B
Revenue by segment
ResMed · $963M total across 2 segments · Q1 2024
- Total Devices$565M—58.6%
- Total Masks and other$398M—41.4%
Forward guidance
ResMed remains focused on delivering lifesaving therapy solutions and accelerating the adoption of digital health in sleep apnea, COPD, and out-of-hospital care.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
+0.1%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+1.2%
Avg return
30 days after
49%
33 / 67 earnings
Positive
+18.7%
Q3 2024
Best reaction
-19.3%
Q2 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | -2.9% | -2.0% | -10.8% | |
| Q2 2026 | -1.5% | +2.1% | -0.5% | |
| Q1 2026 | -1.5% | -2.8% | +1.4% | |
| Q3 2025 | +10.1% | +10.9% | +13.2% | |
| Q2 2025 | -8.3% | -5.8% | -9.4% | |
| Q1 2025 | +7.9% | +2.9% | +2.7% | |
| Q4 2024 | +4.9% | +2.6% | +14.9% | |
| Q3 2024 | +18.7% | +16.4% | +16.0% | |
| Q2 2024 | +6.5% | +9.3% | +5.2% | |
| Q1 2024 | -4.2% | +0.5% | +9.5% | |
| Q4 2023 | -19.3% | -19.3% | -28.3% | |
| Q3 2023 | +7.6% | +5.4% | -3.8% | |
| Q2 2023 | -2.8% | -1.2% | -8.5% | |
| Q1 2023 | -6.5% | -5.6% | -1.7% | |
| Q4 2022 | -1.5% | -3.1% | -3.1% | |
| Q3 2022 | -6.9% | -8.5% | -3.0% | |
| Q2 2022 | -6.5% | +0.5% | +6.2% | |
| Q1 2022 | -1.9% | -2.1% | -6.3% | |
| Q4 2021 | +0.5% | +0.7% | +8.3% | |
| Q3 2021 | -10.6% | -8.6% | -2.0% | |
| Q2 2021 | -5.8% | -3.5% | -9.9% | |
| Q1 2021 | +6.2% | +12.1% | +16.0% | |
| Q4 2020 | -13.4% | -13.6% | -14.4% | |
| Q3 2020 | +1.8% | +2.0% | +2.9% | |
| Q2 2020 | -4.1% | +0.6% | -4.1% | |
| Q1 2020 | +13.8% | +15.7% | +14.6% | |
| Q4 2019 | +1.1% | +3.8% | +5.4% | |
| Q3 2019 | +7.9% | +7.6% | +9.3% | |
| Q2 2019 | -19.3% | -21.5% | -13.6% | |
| Q1 2019 | +6.2% | +7.3% | +5.7% | |
| Q4 2018 | -2.1% | +0.7% | +4.1% | |
| Q3 2018 | -2.1% | -1.4% | +6.9% | |
| Q2 2018 | +13.2% | +15.9% | +5.1% | |
| Q1 2018 | +7.7% | +7.4% | +8.6% | |
| Q4 2017 | -6.0% | -2.6% | +0.6% | |
| Q3 2017 | -5.2% | -2.7% | -2.3% | |
| Q2 2017 | +9.5% | +7.1% | +13.7% | |
| Q1 2017 | -5.0% | -5.3% | -8.7% | |
| Q4 2016 | +5.8% | +6.5% | +6.0% | |
| Q3 2016 | -7.4% | — | — | |
| Q2 2016 | +7.1% | — | — | |
| Q1 2016 | +0.1% | — | — | |
| Q4 2015 | +3.6% | — | — | |
| Q3 2015 | -10.3% | — | — | |
| Q2 2015 | +8.6% | — | — | |
| Q1 2015 | +9.5% | — | — | |
| Q4 2014 | -4.1% | — | — | |
| Q3 2014 | -0.4% | — | — | |
| Q2 2014 | -5.7% | — | — | |
| Q1 2014 | -13.2% | — | — | |
| Q4 2013 | +0.5% | — | — | |
| Q3 2013 | +0.9% | — | — | |
| Q2 2013 | +7.0% | — | — | |
| Q1 2013 | -4.7% | — | — | |
| Q4 2012 | +12.8% | — | — | |
| Q3 2012 | +7.6% | — | — | |
| Q2 2012 | +9.7% | — | — | |
| Q1 2012 | -12.0% | — | — | |
| Q4 2009 | -5.4% | — | — | |
| Q4 2011 | -5.4% | — | — | |
| Q3 2011 | -0.9% | — | — | |
| Q3 2010 | -0.9% | — | — | |
| Q2 2010 | +2.2% | — | — | |
| Q2 2011 | +2.2% | — | — | |
| Q1 2010 | +3.6% | — | — | |
| Q1 2011 | +3.6% | — | — | |
| Q4 2010 | +3.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro